Active, not recruitingPhase 1NCT04007029

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jonsson Comprehensive Cancer Center
Principal Investigator
Sarah Larson, MD
UCLA / Jonsson Comprehensive Cancer Center
Intervention
Chimeric Antigen Receptor T-Cell Therapy(biological)
Enrollment
24 enrolled
Eligibility
18-70 years · All sexes
Timeline
2019 – 2027

Study locations (1)

Collaborators

Parker Institute for Cancer Immunotherapy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04007029 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials